ERBB2 and breast carcinoma: In comparison, abnormalities based on GLS and LVEF were found in 71% and 66% of patients respectively.21 Therefore, in identifying myocardial alterations among HER2-positive breast cancer patients following anticancer therapy, T1 mapping is a favoured method for precisely measuring the particular degree of tissue damage.